
Glowura+ Peptide Pen Kit | GHK-Cu, BPC-157 & TB-500 Research Peptides
Explore the Glowura+ peptide pen kit, which features GHK-Cu, BPC-157, and TB-500, essential compounds in elevating peptide science. Designed for advanced laboratory research, this precision peptide kit supports detailed studies of research laboratory compounds.
Glowura+ is a multi-peptide research formulation that combines GHK-Cu, BPC-157, and TB-500, three widely studied compounds in peptide research. Developed for laboratory environments, this advanced peptide pen kit facilitates investigations into cellular pathways, tissue models, and regenerative research frameworks, making it a valuable addition to RULIA Ltd research products.
The precision delivery format ensures consistent handling, making Glowura+ suitable for controlled experimental protocols where repeatability and accuracy are critical. Each peptide component is commonly explored in research related to cellular signaling, structural protein interactions, and recovery pathways.
Combined GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg)
Designed for laboratory and research environments
Precision-format delivery system
Suitable for multi-pathway peptide research

Elevating peptide science with our high-quality Tirzepatide 40mg research peptide, a dual GLP-1 and GIP receptor agonist designed for advanced metabolic and receptor pathway studies. This compound is a vital part of RULIA Ltd research products, making it essential for modern metabolic and receptor-based research.
Tirzepatide is a dual agonist peptide extensively studied for its interactions with GLP-1 and GIP receptors, playing a significant role in metabolic signaling pathways and receptor activity. Supplied in a precision-controlled format, this 40mg peptide supports consistent laboratory investigation.
In research laboratories, Tirzepatide is frequently explored for its implications in appetite pathway research and energy regulation models. Its dual mechanism presents a valuable opportunity for studies examining complex biological interactions, solidifying its status as a key research laboratory compound.
- 40mg high-purity peptide content
- Dual GLP-1 / GIP receptor interaction
- Suitable for metabolic pathway research
- Precision formulation for laboratory use

Retatrutide 40mg Research Peptide | GLP-1, GIP & Glucagon Agonist
Retatrutide 40mg is a cutting-edge triple agonist peptide specifically designed for elevating peptide science in advanced research. This research laboratory compound allows scientists to investigate the interactions of GLP-1, GIP, and glucagon receptor pathways within laboratory settings.
As a next-generation research peptide, Retatrutide is studied for its unique multi-pathway profile, making it highly relevant for exploring complex metabolic and receptor signaling systems. This peptide is integral to RULIA Ltd research products, facilitating structured experimental use where multi-receptor interaction is a primary focus. Its innovative mechanism enables researchers to delve into broader biological responses across interconnected pathways.
Key Features:
- 40mg triple agonist peptide
- GLP-1, GIP, and glucagon receptor interaction
- Suitable for advanced research models
- Designed for precision and consistency
At RULIA Ltd, we pride ourselves on elevating peptide science by providing high-quality, research laboratory compounds tailored for laboratory professionals and scientific institutions. Our comprehensive catalogue includes a wide selection of RULIA Ltd research products meticulously tested to meet rigorous standards, ensuring reliability and consistency in your experiments. We understand the importance of precision and safety in research environments, which is why all our offerings are intended strictly for research and laboratory use only. Our team is committed to supporting your scientific endeavours by offering expert guidance and exceptional customer service, making us your trusted partner in innovation. Please note that all products are not approved for human consumption, medical use, or therapeutic applications, and must be handled by qualified professionals in controlled settings.